Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥1.82T2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥3.56T2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥1.78T2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥27.2bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥20.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥35.1bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥64.6bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥29.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥39.8bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥32.8bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥21.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥41.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥17.2bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥27.6bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥22.5bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥1.88Tat 2024-09-30Cons.Assets
Total assets¥1.80Tat 2024-03-31Cons.Assets
Total assets¥1.82Tat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥1.12Tat 2024-09-30Cons.Liabilities
Total liabilities¥1.06Tat 2024-03-31Cons.Liabilities
Net assets / equity¥757.7bnat 2024-09-30Cons.Net assets
Net assets / equity¥736.6bnat 2024-03-31Cons.Net assets
Net assets / equity¥714.6bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥251.1bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥230.2bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥249.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥228.1bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥207.0bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥193.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥41.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥61.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥31.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥6.5bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥10.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥14.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥25.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥12.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥103.942024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥195.832023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥80.482023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio32.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.4%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.0bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30¥161m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥58.6bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥600.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥600.2bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥201m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.0bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥1.17T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥11.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥1.83T
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥1.82T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥27.0bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥37m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥56.8bn
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1m
jpcrp040300-q2r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥583.4bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥583.3bn
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥146m
jpcrp040300-q2r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.14T
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.1bn
jpcrp040300-q2r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.78T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥20.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 513
ItemContextValueUnit
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所プライム市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数100株
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口)
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)東京都港区赤坂一丁目8番11号赤坂インターシティAIR
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)株式会社日本カストディ銀行(信託口)
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)東京都中央区晴海一丁目8番12号
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)MPグループメディセオ従業員持株会
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)東京都中央区京橋三丁目1番1号
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)小林製薬株式会社
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)大阪市中央区道修町四丁目4番10号
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMemberText · Plus
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsOtherMember-
Description issued shares voting rightsCurrentQuarterInstant_SharesLessThanOneUnitMember-
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)㈱メディパルホールディングス
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)東京都中央区京橋三丁目1番1号
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYTDDurationText · Plus
Type1 semi annual consolidated financial statements financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus
Quarterly consolidated balance sheet (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of comprehensive income (text)CurrentYTDDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass